Metoprolol Succinate Tablet, Extended Release
Product Images NDC 42806-727

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Metoprolol Succinate (NDC 42806-727). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Epic Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg-1000ct-epic (100mg 1000ct Epic)

The text provides information on metoprolol succinate extended-release tablets with a dosage of 95 mg per tablet. The storage conditions are specified as 20°C to 25°C (68°F to 77°F), with excursions permitted. The medication is equivalent to 100 mg of metoprolol tartrate, USP. The tablets should be dispensed in a tight, light-resistant container with a child-resistant closure. The product is distributed by Epic Pharma, LLC and manufactured by Yichang Humanwell Oral Solid Dosage Plant in Yichang, Hubei, China. Please refer to the original packaging insert for usual dosage guidance.*

FDA Label Image

100mg-100ct-epic (100mg 100ct Epic)

FDA Label Image

100mg-500ct-epic (100mg 500ct Epic)

The text provides dosage information for metoprolol succinate extended-release tablets containing 95 mg, equivalent to 100 mg metoprolol tartrate. It also mentions storage conditions between 20°C to 25°C, with excursions permitted. The medication should be kept out of reach of children, dispensed in a tight, light-resistant container, and is distributed by Epic Pharma, LLC. The manufacturing is done at the EPIC Yichang Humanwell Oral Solid Dosage Plant in Yichang, Hubei, China.*

FDA Label Image

200mg-1000ct-epic (200mg 1000ct Epic)

This text provides instructions for the usual dosage, storage conditions, and dispensing information for a medication containing metoprolol succinate. It also mentions that each extended-release tablet contains 190 mg metoprolol succinate equivalent to 200 mg Extended-Release Tablets, USP metoprolol tartrate, USP. The medication is distributed by Epic Pharma, LLC and manufactured by Yichang Humanwell Oral Solid Dosage Plant in China. The text includes the warning to keep all medications out of reach of children.*

FDA Label Image

200mg-100ct-epic (200mg 100ct Epic)

The text provides information about the usual dosage and storage instructions for a medication containing metoprolol succinate. It is recommended to store the tablets at 20° to 25°C (68° to 77°F), with excursions permitted between 15° to 30°C (59° to 86°F). The package is child-resistant, and each extended-release tablet contains 190 mg of metoprolol succinate, equivalent to 200 mg of metoprolol tartrate, USP. The medication is distributed by a company located in Laurelton, NY, and manufactured in Yichang, Hubei, China. The text also includes a warning to keep all medications out of the reach of children.*

FDA Label Image

200mg-500ct-epic (200mg 500ct Epic)

The text provides information on metoprolol succinate extended-release tablets of the dosage 190 mg. It includes instructions for storage conditions and warnings about keeping the medication out of reach of children. The tablets are to be dispensed in a light-resistant container with a child-resistant closure. The manufacturer is Epic Pharma, LLC and they are distributed by Epic Pharma, LLC from New York.*

FDA Label Image

25mg-1000ct-epic (25mg 1000ct Epic)

This is information about metoprolol succinate extended-release tablets with a dosage of 23.75 mg. It contains a warning to keep medications out of reach of children and is child-resistant. The tablets are manufactured by Yichang Humanwell Oral Solid Dosage Plant in China and distributed by Epic Pharma, LLC.*

FDA Label Image

25mg-100ct-epic (25mg 100ct Epic)

The text provides information regarding the usual dosage of a medication containing 23.75 mg of metoprolol succinate in extended-release tablets. It includes storage instructions, child-resistant packaging details, and the name of the manufacturer. The package insert also mentions temperature storage requirements and a warning about keeping medications out of reach of children. The product is distributed by Epic Pharma and manufactured by Yichang Humanwell Oral Solid Dosage Plant in China.*

FDA Label Image

25mg-500ct-epic (25mg 500ct Epic)

FDA Label Image

50mg-1000ct-epic (50mg 1000ct Epic)

The text provides information about the usual dosage of metoprolol succinate extended-release tablets, their storage conditions, and safety warning. It mentions storing the tablets at a temperature between 20°C to 25°C, dispensing in a child-resistant container, and keeping out of reach of children. The tablets are distributed by Epic Pharma, LLC and manufactured by Yichang Humanwell Oral Solid Dosage Plant in China.*

FDA Label Image

50mg-100ct-epic (50mg 100ct Epic)

The text provides information about a medication containing metoprolol succinate, with a usual dosage specified on the extended-release package insert. It mentions the storage conditions (20° to 25°C or 68° to 77°F) and warns to keep the package out of reach of children. The medication is in tablet form with each tablet containing 47.5 mg of metoprolol succinate. It also includes details about the manufacturer, Epic Pharma, and the distribution and manufacturing locations in Laurelton, NY, and Yichang, Hubei, China, respectively.*

FDA Label Image

50mg-500ct-epic (50mg 500ct Epic)

This text provides general information about the dosage and storage instructions for a medication containing 47.5 mg of metoprolol tartrate. It also mentions that the package is child-resistant and provides details about the manufacturer. The dosage information recommends referring to the package insert for specific details. The medication is in the form of extended-release tablets.*

FDA Label Image

Picture-1 (Picture 1)

Results for Subgroups in MERIT-HF study are compared in terms of all-cause mortality and hospitalization for heart failure. The data is categorized based on factors like NYHA class, ejection fraction, etiology of heart failure, gender, race, medical history such as previous myocardial infarction or diabetes mellitus, and heart rate. The study provides insights into the relative risks and 95% confidence intervals for different subgroups included in the analysis. Overall, the text offers valuable information for evaluating the impact of various factors on outcomes in heart failure patients.*

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.